Exploration of cannabis use and polygenic risk scores on the psychotic symptom progression of a FEP cohort.

Cannabis use is highly prevalent in first-episode psychosis (FEP) and plays a critical role in its onset and prognosis, but the genetic underpinnings promoting both conditions are poorly understood. Current treatment strategies for cannabis cessation in FEP are clearly inefficacious. Here, we aimed...

ver descrição completa

Detalhes bibliográficos
Autores: Gonzàlez Segura, Àlex, Mané Santacana, Anna, Prohens Coll, Llucia, Rodríguez Ferret, Natalia, Mezquida Mateos, Gisela, Cuesta, Manuel J., Vieta i Pascual, Eduard, 1963-, Amoretti Guadall, Silvia, Lobo, Antonio, González-Pinto, Ana, Díaz Caneja, Covadonga M., Roldán, Alexandra, Jiménez Martínez, Esther, Baeza, Inmaculada, 1970-, Legido, Teresa, Saiz Ruiz, Jerónimo, Bernardo Vilamitjana, Mercè, Mas Herrero, Sergi, PEPs Group
Formato: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2023
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/219041
Acesso em linha:https://hdl.handle.net/2445/219041
Access Level:acceso abierto
Palavra-chave:Psicosi
Cànnabis
Esquizofrènia
Genètica
Psychoses
Cannabis
Schizophrenia
Genetics
Descrição
Resumo:Cannabis use is highly prevalent in first-episode psychosis (FEP) and plays a critical role in its onset and prognosis, but the genetic underpinnings promoting both conditions are poorly understood. Current treatment strategies for cannabis cessation in FEP are clearly inefficacious. Here, we aimed to characterize the association between cannabis-related polygenic risk scores (PRS) on cannabis use and clinical course after a FEP. A cohort of 249 FEP individuals were evaluated during 12 months. Symptom severity was measured with the Positive and Negative Severity Scale and cannabis use with the EuropASI scale. Individual PRS for lifetime cannabis initiation (PRSCI) and cannabis use disorder (PRSCUD) were constructed. Current cannabis use was associated with increased positive symptoms. Cannabis initiation at younger ages conditioned the 12-month symptom progression. FEP patients with higher cannabis PRSCUD reported increased baseline cannabis use. PRSCI was associated with the course of negative and general symptomatology over follow-up. Cannabis use and symptom progression after a FEP were modulated by cannabis PRS, suggesting that lifetime initiation and use disorders may have partially independent genetic factors. These exploratory results may be the first step to identify those FEP patients more vulnerable to cannabis use and worse outcomes to ultimately develop tailored treatments.

Registos relacionados